Frank Morgan’s March 31, 2026 Option Exercise Boosts Confidence in Modular Medical

Insider Activity Spotlight: Frank Morgan C. and the March 31 , 2026 Options Exercise

On March 31 , 2026, Frank Morgan C., a member of Modular Medical’s board and an outside director, exercised a pair of fully‑vested options under the company’s Outside Director Compensation Plan. Each transaction covered 250 shares, and both were recorded as “buy” trades, increasing Morgan’s total holdings to 312 shares. The options were exercised at an average price of approximately $4.55 per share—substantially below the prevailing market price of $5.10—resulting in a favorable cost basis for the director.

Implications for Investors

Although the absolute volume of shares involved is modest, the timing of Morgan’s exercise coincides with a broader wave of insider activity on the same day. Several other directors—including Vos Ellen O’Connor, Jeff Goldberg, Philip Brent, Steven Felschwer, and Duane DeSisto—also exercised 250‑share options on March 31. This cluster of transactions indicates a coordinated utilization of the vesting schedule rather than a reaction to any singular market event. For investors, the key takeaway is that the board remains committed to the long‑term upside of Modular Medical. Their cost‑effective purchases reinforce confidence in the company’s trajectory despite recent volatility.

What It Means for the Company’s Future

Modular Medical’s stock has experienced a sharp decline in 2026, sliding 15.66 % in the month and 81.17 % year‑to‑date. The recent 1‑for‑30 reverse split has compressed share counts, yet the company’s market capitalization remains below $24 million. The director exercises at a price well below the trading level suggest that insiders are not alarmed by the decline and are prepared to absorb additional shares at a discount. This may signal that the board believes the technology—particularly the injection‑free delivery system—is still poised for a resurgence.

However, the sheer volume of insider buys is dwarfed by broader market sentiment, which has shown a neutral social‑media tone (sentiment = 0) but moderate buzz (12.35 %). This indicates that the market is not yet fully aligned with insider optimism.

Frank Morgan C.: A Pattern of Strategic Purchases

Frank Morgan’s transaction history reveals a consistent pattern of exercising options in sizeable batches. In both March and September of 2025, he purchased 7,500 and 1,875 options respectively—totaling 9,375 shares each time. These purchases were always executed at the same exercise price of $4.55, mirroring the March 2026 exercise. Morgan’s holdings have grown steadily, reflecting a long‑term commitment. The timing—often shortly after grant dates—suggests a disciplined approach: he exercises as soon as options vest, maintaining a low cost basis and aligning his interests with those of the shareholders.

Takeaway for Financial Professionals

For analysts and portfolio managers, Morgan’s recent activity should be viewed as a positive, albeit incremental, sign of insider confidence. The synchronized exercises across the board hint at a unified endorsement of Modular Medical’s strategy. While the company’s share price remains weak, the directors’ willingness to purchase at a discount underscores their conviction that the underlying technology—and the broader health‑care market—will ultimately drive value. Investors should weigh this insider sentiment against the broader market dynamics and consider a watchful, long‑term perspective rather than reacting to short‑term price swings.